Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival
- 30 May 2017
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 24 (8) , 2206-2212
Abstract
Tumor grade is an important predictor of survival in gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), as determined by Ki-67 expression and mitotKeywords
Funding Information
- NIH T32 Training Grant (T32CA148062)
- Neuroendocrine SPORE Grant (P50CA174521)
This publication has 27 references indexed in Scilit:
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyThe Lancet, 2016
- Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?Surgery, 2016
- Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010Neuroendocrinology, 2015
- Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary TumorNeuroendocrinology, 2015
- Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomesCancer, 2014
- Therapeutic strategies for neuroendocrine liver metastasesCancer, 2014
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2014
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study GroupJournal of Clinical Oncology, 2009
- Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survivalSurgery, 2006